Radiopharmaceuticals Market - Top Companies and Manufacturers

  • Report ID: 6519
  • Published Date: Oct 07, 2024
  • Report Format: PDF, PPT

Companies Dominating the Radiopharmaceuticals Landscape

    There are both large pharmaceutical enterprises and specialized businesses in this competitive sector. Leading companies set themselves apart via technological innovations, intensive research and development, and calculated alliances. While rising players concentrate on specialty technologies and novel medicines, established companies make use of their resources and worldwide reach. Quality and regulatory compliance are vital, and businesses must adhere to strict requirements. Pricing and customer service tactics can have an impact on competition since businesses want to provide value and top-notch assistance. All things considered, the radiopharmaceuticals market is dynamic, propelled by ongoing innovation and a concentration on upholding strict standards for both product development and customer service.

    Here are some leading players in the radiopharmaceuticals market:

    • PharmaLogic Holdings Corp.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Bayer AG
    • Bracco
    • Cardinal Health Inc.
    • Coquí Radiopharmaceuticals Corp
    • Curium Pharma
    • Eli Lilly and Company
    • General Electric Company
    • IRE EliT
    • Bristol Myers Squibb

Browse Key Market Insights with Data Illustration:

In the News

  • In May 2024, PharmaLogic Holdings Corp. announced a new radiopharmaceutical research and production facility in the U.S. to improve patient care and diagnostic results, the new facility will concentrate on creating novel radio-ligand therapeutic and diagnostic medications.
  • In February 2024, Bristol Myers Squibb and RayzeBio, Inc. signed a formal merger agreement to enhance their pharmaceutical product base. According to the deal, Bristol Myers Squibb will pay USD 62.50 in cash per share to acquire RayzeBio, for an expected total equity value of USD 4.1 billion, or USD 3.6 billion net of estimated cash received.

Author Credits:  Radhika Pawar


  • Report ID: 6519
  • Published Date: Oct 07, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The radiopharmaceuticals market size is USD 7.6 billion in 2024.

The global radiopharmaceuticals market size was US 7.6 billion in 2024 and is likely to reach USD 26.6 billion by the end of 2037, expanding at a CAGR of 10.2% over the forecast period, i.e., 2025-2037.

Bayer AG, Bracco, Cardinal Health Inc., Coquí Radiopharmaceuticals Corp, Curium Pharma, Eli Lilly and Company, General Electric Company, IRE EliT, and Bristol Myers Squibb are some key players in the market.

The diagnostics segment is expected to hold a leading share during the forecast period.

North America is projected to offer lucrative prospects with a share of 49.2% in 2025.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample